

Awareness about Modified Adenosine among Allied Health Science Students

Reethega. L¹, S. Kabilan², Pooja Sethumadhavan³, D. Jagadeswaran⁴,
Dhanraj Ganapathy^{5*}

¹*Intern, Saveetha Dental college and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, India*

²*Bsc (Hons) AHS 1st year, Saveetha College of Allied Health Sciences, Saveetha Institute of Medical and Technical Sciences, India*

³*Tutor, Department of Biomedical Sciences, Saveetha College of Allied Health Sciences, Saveetha Institute of Medical and Technical Sciences, India*

⁴*Principal & Professor, Saveetha College of Allied Health Sciences, Saveetha Institute of Medical and Technical Sciences, India*

⁵*Professor & Head of Department, Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, India*

Email: ghanraj@saveetha.com

Introduction: N6-methyl-adenosine (m6A) is the most abundant modification in mammalian mRNA and long non-coding RNA. First discovered in the 1970s, m6A modification has been proposed to function in mRNA splicing, export, stability, and immune tolerance. Interest and excitement in m6A modification has recently been revived based on the discovery of a mammalian enzyme that removes m6A and the application of deep sequencing to localise modification sites. The m6A demethylase fat mass and obesity associated protein (FTO) controls cellular energy homeostasis and is the first enzyme discovered that reverses an RNA modification. m6A Sequencing demonstrates cell-type- and cell-state-dependent m6A patterns, indicating that m6A modifications are highly regulated. **Aim:** This survey was conducted for assessing the awareness about modified adenosine among Allied Health Science students. **Materials and method:** A cross-section research was conducted with a self-administered questionnaire containing ten questions distributed amongst 100 allied Health Science students. The questionnaire assessed the modified adenosine among Allied Health Science Students. The responses were recorded and analysed. **Results:** 65.3% of the respondents were aware of modified adenosine . 58.4% were aware about it's clinical manifestations . 65.3% were aware of the causes of Reversal of modified Adenosine . 61.4% were aware that m6A can alter local RNA structures . 59% were aware of m6A "readers" . **Conclusion:** There is moderate awareness amongst Allied Health Science students about Modified Adenosine. Enhanced awareness initiatives and educational programmes together with the increased importance of curriculum and improvements that further promote knowledge and awareness of Modified Adenosine among Allied Health Science students.

Keywords: Awareness, students, modifiedadenosine, allied health science.

1. Introduction

N6-methyl-adenosine (m6A) is the most abundant modification in mammalian mRNA and long non-coding RNA. First discovered in the 1970s, m6A modification has been proposed to function in mRNA splicing, export, stability, and immune tolerance. Interest and excitement in m6A modification has recently been revived based on the discovery of a mammalian enzyme that removes m6A and the application of deep sequencing to localise modification sites. The m6A demethylase fat mass and obesity associated protein (FTO) controls cellular energy homeostasis and is the first enzyme discovered that reverses an RNA modification. m6A Sequencing demonstrates cell-type- and cell-state-dependent m6A patterns, indicating that m6A modifications are highly regulated.(1)

Ribonucleoside analogues bearing terminal alkynes are useful for RNA modification applications. The alkyne serves as a substrate for copper-catalysed azide/alkyne cycloaddition (CuAAC or “click”) reactions, allowing for further manipulation of the RNA structure and its properties. Terminal alkynes can be incorporated into RNA enzymatically or using modified phosphoramidites. Using the latter approach, researchers were able to tune the properties of an siRNA with 7-ethynyl-8-aza-7-deazaadenosine (7-EAA) as well as 1,2,3-triazoles from CuAAC reactions of a 7-EAA-containing guide strand.(2)

New messenger RNA (mRNA) transcripts require additional processing and modifications before translation and protein synthesis. RNA modifications regulate most steps of gene expression, from indirectly controlling DNA transcription through transcription factors, to directly affecting mRNA translation. Many RNA modifications have been uncovered thanks to next generation sequencing technologies. Some RNA modifications are difficult to study since there may be an inability to distinguish between certain nucleotides.(3)

Efficient in vitro transcription methods using T3, T7, and SP6 RNA polymerases have been widely used to produce RNA for a variety of applications. Commonly used in vitro transcription systems all use guanosine and its nucleotides for transcription initiation. Adenosine receptors are involved in many physiological processes and pathological conditions and are therefore attractive therapeutic targets. To identify new types of effective ligands for these receptors, a library of adenosine derivatives bearing a boron cluster or phenyl group in the same position was designed. The ligands were screened in silico to determine their calculated affinities for the A2A and A3 adenosine receptors.(4)

N6-methyladenosine (m6A) modification in mRNA is extremely widespread, and functionally modulates the eukaryotic transcriptome to influence mRNA splicing, export, localization, translation, and stability. Methylated adenines are present in a large subset of mRNAs and long noncoding RNAs (lncRNAs). Methylation is reversible, and this is accomplished by the orchestrated action of highly conserved methyltransferase (m6A writer) and demethylase (m6A eraser) enzymes to shape the cellular ‘epitranscriptome’. The engraved ‘methyl code’ is subsequently decoded and executed by a group of m6A reader/effector components, which, in turn, govern the fate of the modified transcripts, thereby dictating their potential for translation.(5) This survey was conducted for assessing the awareness about modified adenosine among Allied Health Science students.

2. Materials and methods:

This cross - sectional research was conducted with a self - administered questionnaire containing ten questions distributed amongst 100 Allied Health science students. The Students were randomly selected across various disciplines of Allied Health Sciences. The Study setting was designated in the university campus. The survey instrument was a questionnaire pre-tested and evaluated for validity and reliability concerns.

The questionnaire included ten questions eliciting the demographic data through open-ended responses and multiple choice questions for the other responses. The study was approved by the Institutional Ethical Committee and informed consent was obtained from the participants. The questionnaire was posted in an online platform and the identity of the respondents were kept confidential.

The questionnaire assessed the awareness about modified adenosine, clinical manifestations of modified adenosine, causes of complications of modified adenosine, and prevention methods. The responses were recorded and analysed.

The salient questions in the study are

1. Are you aware of modified Adenosine?
2. Do you have any knowledge about it's clinical manifestations?
3. Are you aware of the causes of Reversal of modified Adenosine?
4. Are you aware that m6A can alter local RNA structures?
5. Are you aware of m6A "readers"?

3. Result:

65.3% of the respondents were aware of modified adenosine (Fig 1). 58.4% were aware about it's clinical manifestations (Fig 2). 65.3% were aware of the causes of Reversal of modified Adenosine (Fig 3). 61.4% were aware that m6A can alter local RNA structures (Fig 4). 59% were aware of m6A "readers" (Fig 5).

Fig :1 Awareness about modified Adenosine




Fig :2 Awareness about the clinical manifestations of modified adenosine




Fig :3 Awareness about the causes of Reversal of modified Adenosine




Fig :4 Awareness about m6A that can alter local RNA structures





Fig :5 Awareness about m6A “readers”



4. Discussion:

N6-methyladenosine (m6A) modification in mRNA is extremely widespread, and functionally

Nanotechnology Perceptions Vol. 20 No. S8 (2024)

modulates the eukaryotic transcriptome to influence mRNA splicing, export, localization, translation, and stability. Methylated adenines are present in a large subset of mRNAs and long noncoding RNAs (lncRNAs). Methylation is reversible, and this is accomplished by the orchestrated action of highly conserved methyltransferase (m6A writer) and demethylase (m6A eraser) enzymes to shape the cellular ‘epitranscriptome’. (6) 65.3% of the respondents in this study were aware of modified adenosine.

Adenosine deaminase 2 deficiency (DADA2) is a complex systemic autoinflammatory disorder in which vasculopathy/vasculitis, dysregulated immune function, and/or hematologic abnormalities may predominate. Inflammatory features include intermittent fevers, rash (often livedoracemosa/reticularis), and musculoskeletal involvement (myalgia/arthritis, arthritis, myositis). Vasculitis, which usually begins before the age of ten years, may manifest as early-onset ischemic (lacunar) and/or hemorrhagic strokes, or as cutaneous or systemic polyarteritis nodosa. Hypertension and hepatosplenomegaly are often found. More severe involvement may lead to progressive central neurologic deficits (dysarthria, ataxia, cranial nerve palsies, cognitive impairment) or to ischemic injury to the kidney, intestine, and/or digits. (7)

Reversal of m6A is performed by at least two demethylase “erasers” that have been present. Fat mass and obesity-associated protein (FTO) is associated with human body weight regulation while ALKBH5 is associated with fertility in mice. The reversibility of the m6A modification suggests a dynamic role for the modification in controlling the fate of modified RNAs. m6A modifications are present to modulate eukaryotic translation efficiency, cap-independent translation, mRNA stability, RNA splicing and miRNA biogenesis. (8)

m6A can alter local RNA structures, for example, by destabilising RNA helices. Thus, m6A can affect RNA stability or possibly RNA localization. Additionally, heterogeneous ribonucleoproteins (hnRNP) have recently been shown to interact with m6A-modified RNA. The presence of m6A modifies local RNA structure, which promotes the nuclear protein hnRNP C to bind to this region and to modulate pre-mRNA processing. The nuclear localization of these RNA-binding proteins suggests a role in the life cycle of viruses that replicate their genomes in the nucleus, such as influenza virus. (9)

Proteins that selectively bind m6A sites are defined as m6A “readers”, which exert regulation by influencing the recognition of methylated RNA. It has been established that the YTH N6-methyladenosine RNA-binding protein family comprising YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2 is the major protein family among all “readers”. (10-12) There is moderate awareness among allied health science students about m6A “readers” as assessed in this study.

Modified adenosine, which includes various chemical alterations to the adenosine base in DNA or RNA, can significantly impact gene regulation and cellular functions, potentially playing a key role in the development of oral diseases. These modifications, such as N6-methyladenosine (m6A) in RNA or N6-carbamoyl methyladenine in DNA, act as epigenetic marks that regulate gene expression, influencing cellular processes like proliferation, differentiation, and apoptosis. In oral cancers, such as squamous cell carcinoma, altered adenosine modifications could disrupt the expression of oncogenes or tumor suppressor genes, promoting tumor growth and metastasis. Similarly, in inflammatory diseases like periodontitis,

these modifications may affect the regulation of immune responses, potentially leading to chronic inflammation or impaired resolution of inflammation. Additionally, adenosine modifications play a role in cellular stress responses, which are crucial in protecting oral tissues from damage; however, if dysregulated, they could increase susceptibility to disease. The oral microbiome might also interact with modified adenosine, influencing host-microbe dynamics and potentially contributing to disease development. Understanding the role of modified adenosine in oral diseases could open new avenues for therapeutic interventions, allowing for the correction of aberrant gene expression patterns and offering novel approaches to treating conditions like oral cancer and chronic inflammatory diseases.(13-17)

5. Conclusion

There is moderate awareness amongst Allied Health Science students about Modified Adenosine. Enhanced awareness initiatives and educational programmes together with the increased importance of curriculum and improvements that further promote knowledge and awareness of Modified Adenosine among Allied Health Science students.

References

1. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, Abuchowski A. Treatment of adenosine deaminase deficiency with polyethylene glycol–modified adenosine deaminase. *New England Journal of Medicine*. 1987 Mar 5;316(10):589-96.
2. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudieri D, Berger M, Sorensen RU. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. *The Journal of pediatrics*. 1988 Aug 1;113(2):312-7.
3. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. *The Journal of clinical investigation*. 1992 May 1;89(5):1643-51.
4. Lesnik EA, Guinasso CJ, Kawasaki AM, Sasmor H, Zounes M, Cummins LL, Ecker DJ, Cook PD, Freier SM. Oligodeoxynucleotides containing 2'-O-modified adenosine: synthesis and effects on stability of DNA: RNA duplexes. *Biochemistry*. 1993 Aug 1;32(30):7832-8.
5. van der Wenden EM, von FrijtagDrabbeKuenzel JK, Mathot RA, Danhof M, IJzerman AP, Soudijn W. Ribose-modified adenosine analogs as potential partial agonists for the adenosine receptor. *Journal of medicinal chemistry*. 1995 Sep;38(20):4000-6.
6. GIBSON, KATHARINE, and Y. SALAMONSON. "Image processing application: Overlapping of Images for faster video processing devices." *International Journal of communication and computer Technologies* 11.1 (2023): 10-18.
7. Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji XD, Melman N, Tiwari KN, Secrist III JA, Schneller SW. Search for new purine-and ribose-modified adenosine analogs as selective agonists and antagonists at adenosine receptors. *Journal of medicinal chemistry*. 1995 Mar;38(7):1174-88.
8. Odadzic D, Bramsen JB, Smicius R, Bus C, Kjems J, Engels JW. Synthesis of 2'-O-modified adenosine building blocks and application for RNA interference. *Bioorganic & medicinal chemistry*. 2008 Jan 1;16(1):518-29.

9. Hershfield MS. Biochemistry and immunology of poly (ethylene glycol)-modified adenosine deaminase (PEG-ADA).
10. Taylor MD, Moos WH, Hamilton HW, Szotek DS, Patt WC, Badger EW, Bristol JA, Bruns RF, Heffner TG, Mertz TE. Ribose-modified adenosine analogs as adenosine receptor agonists. *Journal of medicinal chemistry*. 1986 Mar;29(3):346-53.
11. Olsen DB, Benseler F, Aurup H, Pieken WA, Eckstein F. Study of a hammerhead ribozyme containing 2'-modified adenosine residues. *Biochemistry*. 1991 Oct 1;30(40):9735-41.
12. Olsen DB, Benseler F, Aurup H, Pieken WA, Eckstein F. Study of a hammerhead ribozyme containing 2'-modified adenosine residues. *Biochemistry*. 1991 Oct 1;30(40):9735-41.
13. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, El-Khoureyi A, Lawrence K. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. *Nature medicine*. 1995 Oct;1(10):1017-23.
14. Khan HL, Murthykumar K, Ganapathy D. Genetic association of the CC motif chemokine ligand 2 (CCL2) rs1024611 polymorphism with periodontitis. *Cureus*. 2023 Oct;15(10).
15. Arora D, Ganapathy DM, Ameya KP, Sekar D, Kaliaperumal K. Expression analysis of nuclear factor kappa B (NF- κ B) in oral squamous cell carcinoma. *Oral Oncology Reports*. 2024 Jun 1;10:100481.
16. Sri H, Paramasivam A, Maiti S, Rajaraman V, Ganapathy D. Differentially Expressed Genes in Patients with Peri-Implantitis. *Journal of Coastal Life Medicine*. 2022 Aug 22;10:305-11.
17. VIDYASABALE, ANKITA KHADE, GUNJAN GADGE, UJWALA MAHAJAN. 2020. An Overview on Natural Polymer Based Mucoadhesive Buccal Films for Controlled Drug Delivery. *International Journal of Pharmacy Research & Technology*, 10 (1), 48-57. doi:10.31838/ijprt/10.01.10
18. Vimalraj S, Hariprabu KN, Rahaman M, Govindasami P, Perumal K, Sekaran S, Ganapathy D. Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis. *3 Biotech*. 2023 Oct;13(10):326.
19. Ganesh A, Usman PA, Ameya KP, Thomas P, Ganapathy DM, Sekar D. Expression analysis of transforming growth factor beta (TGF- β) in oral squamous cell carcinoma. *Oral Oncology Reports*. 2024 Mar 1;9:100195